Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume -, Issue -, Pages 1-8
Publisher
Informa UK Limited
Online
2021-02-17
DOI
10.1080/14656566.2021.1876664
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- (2020) David S Hong et al. LANCET ONCOLOGY
- Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.
- (2020) Christian Diego Rolfo et al. JOURNAL OF CLINICAL ONCOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
- (2020) Kyriakos P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- 1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer
- (2020) M.E. Cabanillas et al. ANNALS OF ONCOLOGY
- 131P NTRK1/2/3 fusions in secretory versus non-secretory breast cancers
- (2020) T. Wilson et al. ANNALS OF ONCOLOGY
- 542P Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients
- (2020) A. Italiano et al. ANNALS OF ONCOLOGY
- Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
- (2020) Lori J. Wirth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Larotrectinib in adult patients with solid tumours: a multicentre, open-label, phase I dose-escalation study
- (2019) D S Hong et al. ANNALS OF ONCOLOGY
- Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS
- (2019) Jing Wang et al. MODERN PATHOLOGY
- Testing algorithm for identification of patients with TRK fusion cancer
- (2019) Frédérique Penault-Llorca et al. JOURNAL OF CLINICAL PATHOLOGY
- ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
- (2019) C Marchiò et al. ANNALS OF ONCOLOGY
- A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas
- (2019) Chia-Chi Lin et al. BRITISH JOURNAL OF CANCER
- NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
- (2019) James P. Solomon et al. MODERN PATHOLOGY
- Resistance to TRK inhibition mediated by convergent MAPK pathway activation
- (2019) Emiliano Cocco et al. NATURE MEDICINE
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
- (2019) Scott Kopetz et al. NEW ENGLAND JOURNAL OF MEDICINE
- TRK inhibitors in TRK fusion-positive cancers
- (2019) A Drilon ANNALS OF ONCOLOGY
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer
- (2018) Benjamin J. Solomon et al. JOURNAL OF CLINICAL ONCOLOGY
- The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII
- (2018) Antonietta Rosella Farina et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
- (2018) Theodore W Laetsch et al. LANCET ONCOLOGY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Use of Neoadjuvant Larotrectinib in the Management of Children With Locally Advanced TRK Fusion Sarcomas
- (2018) Steven G. DuBois et al. CANCER
- A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1).
- (2018) Alexander E. Drilon et al. JOURNAL OF CLINICAL ONCOLOGY
- Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
- (2018) Alexander Drilon et al. Cancer Discovery
- TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening
- (2018) Catherine M. Albert et al. JOURNAL OF CLINICAL ONCOLOGY
- NTRK fusion-positive cancers and TRK inhibitor therapy
- (2018) Emiliano Cocco et al. Nature Reviews Clinical Oncology
- TRK Inhibition: A New Tumor-Agnostic Treatment Strategy
- (2018) Shivaani Kummar et al. Targeted Oncology
- Detecting NTRK, ROS1, and ALK gene fusions in gastrointestinal tumor patients.
- (2017) Steven James Potts et al. JOURNAL OF CLINICAL ONCOLOGY
- ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
- (2017) Filippo Pietrantonio et al. JNCI-Journal of the National Cancer Institute
- Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
- (2017) Alison M. Schram et al. Nature Reviews Clinical Oncology
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors
- (2017) Alexander Drilon et al. Cancer Discovery
- ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
- (2017) Filippo Pietrantonio et al. JNCI-Journal of the National Cancer Institute
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- (2016) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
- (2015) Filippo Pietrantonio et al. EUROPEAN JOURNAL OF CANCER
- An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
- (2015) R. C. Doebele et al. Cancer Discovery
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- TRKing Down an Old Oncogene in a New Era of Targeted Therapy
- (2014) Aria Vaishnavi et al. Cancer Discovery
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
- (2013) Aria Vaishnavi et al. NATURE MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now